Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children

Bibhuti B Das1

  • 1Department of Pediatrics, Division of Pediatric Cardiology, University of Mississippi Medical Center, Jackson, MS 39216, USA.

Insights

Pediatric pulmonary hypertension (PH) causes right ventricular failure (RVF) due to pulmonary vascular changes, often linked to congenital heart disease (CHD). New treatments are needed to reverse RV remodeling and improve outcomes in children.

Area of Science:

  • Cardiology
  • Pediatric Pulmonology
  • Cardiovascular Research

Background:

  • Pulmonary hypertension (PH) is a progressive disorder causing right ventricular strain and failure (RVF).
  • Pediatric PH management differs from adults due to congenital heart disease (CHD) prevalence and developmental factors.
  • CHD, especially unrepaired shunts, is a primary driver of PH in children, leading to vascular remodeling.

Purpose of the Study:

  • To analyze the mechanisms of RVF in PH, considering adult and pediatric specificities.
  • To review current pharmacological and interventional treatments for pediatric PH.
  • To emphasize the need for novel therapies targeting RV remodeling in children.

Main Methods:

  • Comprehensive analysis of RVF mechanisms in PH.
  • Incorporation of adult clinical studies and experimental models.
  • Highlighting unique pediatric considerations in PH and RVF.

Main Results:

  • PH leads to increased pulmonary vascular resistance (PVR), RV strain, and RVF.
  • Elevated pulmonary blood flow from left-to-right shunts can cause progressive vascular remodeling.
  • Current treatments focus on reducing PVR, but RV function improvement is challenging.

Conclusions:

  • Pediatric PH requires tailored management due to CHD and developmental dynamics.
  • Novel therapeutic strategies are essential to directly reverse RV remodeling.
  • Further research into disease-modifying treatments is crucial for improving long-term outcomes in children with PH.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
120
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
107
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
126
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
100
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
101
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
110